Drug for weight loss lowers type 2 diabetes risk in obese patients

10/11/2013 | MedPage Today (free registration)

Overweight and obese patients who took the weight-loss drug Qsymia, which combines phentermine and topiramate extended release, were 70.5% to 78.7% less likely than those in the placebo group to develop type 2 diabetes, a study found. Patients in the Qsymia arm also showed greater weight loss at 108 weeks compared with the controls, researchers wrote in Diabetes Care.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Chief Medical Officer
Meritus
Tempe, AZ
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX